[HTML][HTML] Bacille Calmette Guérin (BCG) and new TB vaccines: Specific, cross-mycobacterial and off-target effects
Abstract The Bacille Calmette Guérin (BCG) vaccine was developed over a century ago and
has become one of the most used vaccines without undergoing a modern vaccine …
has become one of the most used vaccines without undergoing a modern vaccine …
[HTML][HTML] Vaccine development against tuberculosis before and after Covid-19
SHE Kaufmann - Frontiers in Immunology, 2023 - frontiersin.org
Coronavirus disease (Covid-19) has not only shaped awareness of the impact of infectious
diseases on global health. It has also provided instructive lessons for better prevention …
diseases on global health. It has also provided instructive lessons for better prevention …
Postinfectious epigenetic immune modifications—a double-edged sword
AR DiNardo, MG Netea… - New England Journal of …, 2021 - Mass Medical Soc
Effects of Infection on Natural Immunity Antigen-nonspecific host defenses are altered by
infections, with epigenetic changes in the effector cells of natural immunity. Some of these …
infections, with epigenetic changes in the effector cells of natural immunity. Some of these …
Recent advances in the development of protein-and peptide-based subunit vaccines against tuberculosis
The World Health Organization (WHO) herald of the “End TB Strategy” has defined goals
and targets for tuberculosis prevention, care, and control to end the global tuberculosis …
and targets for tuberculosis prevention, care, and control to end the global tuberculosis …
Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo …
AP Tkachuk, EN Bykonia, LI Popova, DA Kleymenov… - Vaccines, 2020 - mdpi.com
GamTBvac is a candidate tuberculosis vaccine with two fusion proteins, containing Ag85a,
ESAT6, CFP10, and a dextran-binding domain (DBD). Phase II of a double-blind …
ESAT6, CFP10, and a dextran-binding domain (DBD). Phase II of a double-blind …
[HTML][HTML] Precision vaccine development: cues from natural immunity
Traditional vaccine development against infectious diseases has been guided by the
overarching aim to generate efficacious vaccines normally indicated by an antibody and/or …
overarching aim to generate efficacious vaccines normally indicated by an antibody and/or …
Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
AD White, AC Tran, L Sibley, C Sarfas… - Frontiers in …, 2023 - frontiersin.org
Tuberculosis remains a major health threat globally and a more effective vaccine than the
current Bacillus Calmette Guerin (BCG) is required, either to replace or boost it. The Spore …
current Bacillus Calmette Guerin (BCG) is required, either to replace or boost it. The Spore …
Emerging prevention and treatment strategies to control COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has now become a serious global threat after …
coronavirus disease 2019 (COVID-19), has now become a serious global threat after …
Is mapping the BCG vaccine‐induced immune responses the key to improving the efficacy against tuberculosis?
In recent years, the century‐old Mycobacterium bovis Bacillus Calmette–Guérin (BCG)
vaccine against tuberculosis (TB) has been re‐evaluated for its capacity to stem the global …
vaccine against tuberculosis (TB) has been re‐evaluated for its capacity to stem the global …
Vaccination with BCGΔBCG1419c protects against pulmonary and extrapulmonary TB and is safer than BCG
MJ Aceves-Sánchez, MA Flores-Valdez… - Scientific Reports, 2021 - nature.com
A single intradermal vaccination with an antibiotic-less version of BCGΔBCG1419c given to
guinea pigs conferred a significant improvement in outcome following a low dose aerosol …
guinea pigs conferred a significant improvement in outcome following a low dose aerosol …